STUDY: L00070 IN 309 F0
Agenda - 100% Radio
Urovant's Gemtesa (vibegron) Receives the US FDA's Approval for Overactive Bladder
Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
Pierre Fabre receives positive CHMP opinion for BRAFTOVI® (encorafenib) in combination with cetuximab for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer | Business Wire
Moving on from Novartis, Array inks a $455M oncology deal with Pierre Fabre | Fierce Biotech
LABORATORY CORPORATION OF AMERICA HOLDINGS 2022 NPS
Positive Phase III data for Pierre Fabre and Array BioPharma
PharmaShots Interview: Pierre Fabre' Roberta Valenti Shares Insights on Nerlynx (neratinib) for the Treatment of HER2 Early Breast Cancer
Upcoming events – Beacons of hope for Array and Proteon | Evaluate
Pharmaceutical Laboratory : Recruitment | Pierre Fabre
Trust & Expectations – Helping Philippe Jardin become VP at Pierre Fabre - Boyd & Moore Executive Search
Pharmaceutical Laboratory : Recruitment | Pierre Fabre
Articles about Atara Biotherapeutics, Inc. | page 2
Athira's Alzheimer's Drug Passes Futility Analysis; Data Targeted For 2024 :: Scrip
Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer | Business Wire
Xavier FOUILLAND - Direction de la Performance - Pierre Fabre Group | LinkedIn
Untitled
PIERRE-FABRE | Business Wire
